We recently published our article 10 Best Cheap AI Medicine Stocks to Buy Now. In this piece, we take a closer look at Schrödinger Inc. (NASDAQ:SDGR) to examine its latest developments, pipeline progress, and why it continues to draw attention from investors.

Artificial intelligence is no longer limited to chatbots, digital advertising and Silicon Valley experiments. It is moving into hospitals, laboratories and pharmaceutical research, where algorithms are helping scientists discover potential medicines, interpret medical images, analyze genetic information and identify treatments suited to individual patients.

Interestingly, the termx term “artificial intelligence” was introduced in 1956, but medical AI took decades to become commercially practical. Modern healthcare systems now generate enormous amounts of clinical, imaging and genomic data—the exact type of information machine-learning models are designed to analyze.

Why Medicine Could Be AI’s Next Major Market

Drug development has traditionally required years of research, costly clinical trials and thousands of unsuccessful experiments. AI drug discovery platforms cannot eliminate those risks, but they can help researchers screen molecules, predict biological interactions and prioritize the most promising candidates before expensive trials begin.

Medical imaging has also become one of the earliest real-world applications of artificial intelligence in healthcare. AI-powered diagnostics can assist doctors in detecting abnormalities, improving image quality and prioritizing urgent cases. Meanwhile, precision medicine platforms are using clinical and genomic data to help match patients with more appropriate treatments.

These developments have encouraged investors to search for the best AI healthcare stocks, AI biotech stocks and medical AI companies positioned to benefit from the industry’s long-term expansion.

A Low Share Price Does Not Always Mean Cheap

A stock trading below $10 may look affordable, but it can still be overvalued if the company generates little revenue, loses money and repeatedly issues new shares. On the other hand, a profitable healthcare technology company trading above $50 may be undervalued when its earnings, cash flow and competitive advantages support a higher valuation.

The most attractive cheap AI medicine stocks therefore combine genuine medical applications with reasonable valuations, sufficient cash reserves, improving financial performance and meaningful long-term growth opportunities.

Finding the Best AI Medicine Stocks

This ranking evaluates NYSE- and Nasdaq-listed companies based on their AI exposure, valuation, revenue growth, financial strength, clinical potential and competitive position. Higher-risk companies were penalized for heavy losses, shareholder dilution, limited cash runways and uncertain paths to profitability.

The countdown begins with the most speculative AI medicine stock at No. 10 and ends with the strongest overall risk-adjusted pick at No. 1. These companies operate across AI drug discovery, precision medicine, genomic analysis, medical imaging, digital health and clinical research—some of the most promising fields where artificial intelligence could reshape modern healthcare.

CHECK THIS OUT: Top 10 Healthcare Stocks to Buy With $1000 in 2026 and 10 Best Medicine Stocks That Could Make Investors 100% Richer.

Our Methodology

For the 10 Cheap AI Medicine Stocks That Could Make You a Millionaire, we ranked each company based on its valuation, medical AI exposure, revenue growth, financial strength, clinical potential and overall investment risk.

10 Best Cheap AI Medicine Stocks to Buy Now

7. Schrödinger Inc. (NASDAQ:SDGR)

Schrödinger, Inc. (NASDAQ: SDGR) reaches seventh place because it offers something many speculative AI medicine companies lack: an established software operation that already generates meaningful revenue.

The company combines physics-based molecular modeling with machine learning to help researchers predict how potential drugs may interact with biological targets. Pharmaceutical and biotechnology customers use the software to evaluate molecules before committing time and money to laboratory experiments. The company also applies the platform to its own drug-discovery pipeline.

This dual business model creates two possible sources of long-term value. Software subscriptions can produce recurring revenue, while successful proprietary medicines or collaborations could generate milestones and royalties. The software business also provides commercial evidence that outside researchers find the underlying technology useful.

Total revenue reached $255.9 million in 2025, increasing 23.3%. Software revenue advanced 10.6% to $199.5 million, while drug-discovery revenue more than doubled to $56.4 million. Software gross margin reached 74%, demonstrating the attractive economics of the established technology operation. Cash, restricted cash and marketable securities stood at $418.8 million after the second quarter of 2026. The latest cash position and financial outlook were reported in the company’s quarterly results.

At approximately $20.09 per share and a market capitalization of about $1.5 billion, the market is assigning a relatively modest value to the software platform, proprietary pipeline and cash reserves. Nevertheless, the company continues to report losses, and drug-discovery revenue can fluctuate depending on collaboration milestones.

The stock offers a more balanced approach to computational drug discovery than many clinical-stage competitors. Investors receive exposure to AI-assisted pharmaceutical research without depending entirely on a single experimental treatment, although clinical and execution risks remain high.

YOU MUST READ THIS: Top 10 Healthcare Stocks to Buy With $1000 in 2026

Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.